Free Alerts   Login
Health Care › Dental Equipment And Supplies

BMRA Stock Price Correlated With Biomerica Financials

BMRA Stock Price vs. Quarterly
BMRA
Income Statement
Cash Flow
Balance Sheet

BMRA Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

BMRA Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

BMRA Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Granahan Investment Management/Ma
1,082,672 sh
-80,148 sh
-7%
$1,353
$353
Wasatch Advisors
953,264 sh
 
$1,192
Vanguard Group
609,365 sh
42,833 sh
8%
$762
$275
Russell Investments Group,.
201,563 sh
26,288 sh
15%
$252
$101
Potomac Capital Management.
167,700 sh
-3,819 sh
-2%
$210
$62
Blackrock.
149,707 sh
-462 sh
0%
$187
$58
Geode Capital Management
120,784 sh
 
$151
Susquehanna International Group,
75,916 sh
64,636 sh
573%
$95
$85
Captrust Financial Advisors
58,668 sh
400 sh
1%
$73
$23
Perritt Capital Management
42,500 sh
 
$53
State Street
37,231 sh
 
$47
Fore Capital
34,680 sh
15,000 sh
76%
$43
$26
Heritage Investors
34,598 sh
-35,750 sh
-51%
$43
-$17
Gwm Advisors
32,700 sh
 
$41
Advisor Group Holdings.
21,000 sh
17,879 sh
573%
$26
$23
Penn Capital Management Co
20,900 sh
-4,829 sh
-19%
$26
$4
Northernrp
20,826 sh
 
$26
Lpl Financial
15,175 sh
15,175 sh
NEW
$19
$19
Two Sigma Securities
14,607 sh
14,607 sh
NEW
$18
$18
Raymond James Financial Services Advisors.
14,500 sh
-3,030 sh
-17%
$18
$3
COMPANY PROFILE
NOTE 1:    ORGANIZATION Biomerica Inc. and Subsidiaries (collectively the “Company”, “Biomerica”, “we”, “us”, or “our”) develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians' offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Our primary focus is the research and development of revolutionary, patented, diagnostic-guided therapy (“DGT”) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. Our medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic, in March 2020 we began redirecting and focusing a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. During fiscal 2021, we sold 2 primary types of Covid 19 tests; 1) antibody diagnostic tests that use a patient’s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body’s immune response to a COVID-19 infection, even if the infection was asymptomatic, and 2) antigen tests that use a patient’s nasal fluid sample to detect if a patient is currently infected with the virus. Aside from the COVID-19 products we offer, the other products we sell are primarily focused on gastrointestinal diseases, food intolerances, diabetes and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country’s regulatory agency.  In addition, some products are cleared for sale in the U.S. by the FDA.

Free historical financial statements for Biomerica Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 22 quarters since 2018. Compare with BMRA stock chart to see long term trends.

Data imported from Biomerica Inc SEC filings. Check original filings before making any investment decision.